Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-positive result or high-risk pathological feature research hub

A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION Lung12)

This study looks at new treatments for early-stage lung cancer, specifically adenocarcinoma non-small cell lung cancer, after surgery. It compares a new drug combination, Datopotamab Deruxtecan with Rilvegostomig, or Rilvegostomig alone, against current standard treatments to see which works best at preventing the cancer from coming back.